Lexicon Pharmaceuticals, Inc. (Nasdaq:LXRX), a biopharmaceutical company focused on developing breakthrough treatments for human disease, updated its drug development progress and reported financial results for the three months ended March 31, 2014. Research and Development Expenses: Research and development expenses for the three months ended March 31, 2014 increased 18 percent to $24.0 million from $20.3 million for the corresponding period in 2013, primarily due to increases in external clinical research and development costs, as well as severance costs as a result of the restructuring announced in January 2014 as Lexicon focuses its resources on late-stage drug development. Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) weekly performance is -0.70%. On last trading day company shares ended up $1.41. Analysts mean target price for the company is $2.83. Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) distance from 50-day simple moving average (SMA50) is -13.18%.
SIGA Technologies Inc (NASDAQ:SIGA) was downgraded by Zacks from a “neutral” rating to an “underperform” rating in a note issued to investors on Monday,StockRatingsNetwork.com reports. They currently have a $2.70 price target on the stock. Zacks‘s price target suggests a potential downside of 2.00% from the company’s current price. SIGA Technologies, Inc. (NASDAQ:SIGA) shares advanced 0.75% in last trading session and ended the day on $2.68. Its return on assets is -10.40 %. SIGA Technologies, Inc. (NASDAQ:SIGA) quarterly performance is -20.24%.
Threshold Pharmaceuticals, Inc. (NASDAQ:THLD) announced that new clinical data from two ongoing Phase 1/2 clinical trials of its investigational hypoxia-activated prodrug, TH-302, will be presented during poster highlight sessions on Friday, May 30, 2014, at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO), taking place May 30 – June 3, 2014, in Chicago, Illinois. The presentations will report early data from an investigator-sponsored trial evaluating TH-302 with bevacizumab (Avastin®) for the treatment of patients with glioblastoma following bevacizumab failure (Abstract #2029), and from a Company-sponsored trial evaluating TH-302 with low-dose dexamethasone in patients with relapsed/refractory multiple myeloma (Abstract #8534). Threshold Pharmaceuticals, Inc. (NASDAQ:THLD) shares moved down -2.43% in last trading session and was closed at $3.62, while trading in range of $3.51 – $3.71. Threshold Pharmaceuticals, Inc. (NASDAQ:THLD) year to date (YTD) performance is -22.48%.
Sorrento Therapeutics, Inc. (NASDAQ:SRNE) a late-stage clinical oncology company developing new treatments for cancer and its associated pain, announced the pricing of an underwritten public offering of 4,765,000 shares of common stock at a public offering price of $5.25 per share. The gross proceeds to Sorrento from this offering are expected to be approximately $25,000,000, before deducting underwriting discounts and commissions and other estimated offering expenses payable by the Company. Sorrento has granted the underwriters a 45-day option to purchase up to an aggregate of 714,750 additional shares of its common stock to cover over-allotments, if any. The offering is expected to close on or about May 20, 2014, subject to customary closing conditions. Sorrento Therapeutics Inc (NASDAQ:SRNE) ended the last trading day at $5.00. Company weekly volatility is calculated as 8.57% and price to cash ratio as 4.39. Sorrento Therapeutics Inc (NASDAQ:SRNE) showed a negative weekly performance of -37.42%.
Stemline Therapeutics Inc (NASDAQ:STML) had its buy rating reaffirmed by analysts at Roth Capital. Stemline Therapeutics Inc (NASDAQ:STML) weekly performance is -9.48%. On last trading day company shares ended up $12.89. Analysts mean target price for the company is $57.00. Stemli,ne Therapeutics Inc (NASDAQ:STML) distance from 50-day simple moving average (SMA50) is -30.38%.
Leave a Reply